Transparency over chemicals: key tools for industry
This article was originally published in Clinica
Consumers and purchasers in general are increasingly keen and able to scrutinise potentially harmful chemicals that may be in products they buy. And this will be of particular concern in an area where patients may already be weak or vulnerable.
You may also be interested in...
Where are the biggest challenges for notified bodies and manufacturers now there is some experience with the MDR, and can the sector manage the new regulatory requirements successfully?
The European Commission has finally published detailed guidance on the EU IVDR’s classification rules. The IVDR’s completely new classification regime means guidance is urgently needed.
Do you know how to avoid the pitfalls when it comes to clinical evidence under the MDR? Or whether evidence gathered outside the US counts? Amie Smirthwaite of Maetrics answers these and other pivotal questions in this third and final part of an interview series with Medtech Insight.